SCHEMBL22925087

SCHEMBL22925087

O=C(Cc1cc(F)cc(F)c1)c1ccc(O)cc1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.77
HTT P42858 3/20 0.77
SMN1; SMN2 Q16637 2/20 0.77
ESR1 P03372 1/20 0.70
SHBG P04278 1/20 0.70
ESR2 Q92731 1/20 0.70
MAPT P10636 4/20 0.62
RAB9A P51151 3/20 0.62
NPC1 O15118 2/20 0.62
GAA P10253 2/20 0.62
ALOX12 P18054 1/20 0.62
ALDH1A1 P00352 4/20 0.59
MAPK1 P28482 2/20 0.59
MEN1 O00255 2/20 0.57
HPGD P15428 2/20 0.57
KMT2A Q03164 2/20 0.57
ALOX5 P09917 1/20 0.57
CYP3A4 P08684 1/20 0.57
ATM Q13315 1/20 0.57
HSP90AB1 P08238 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29574422 1.00 LMNA (0.77) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL3958571 0.87 LMNA (1.00) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL17838467 0.87 LMNA (0.58) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL18176742 0.85 LMNA (0.69) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL312243 0.82 ESR1 (1.00) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL30503014 0.82 ESR1 (1.00) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL11566 0.81 MAPT (0.53) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL22672221 0.80 ESR1 (0.81) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL30497946 0.79 ESR1 (0.80) LMNAHTTSMN1; SMN2ESR1SHBG
SCHEMBL146018 0.79 ESR1 (0.80) LMNAHTTSMN1; SMN2ESR1SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11014915-B2 Selective estrogen receptor degrader SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-05-25 US disclosed
US-20210024504-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADER SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-01-28 US disclosed
WO-2021014386-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADER SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024504-A1 SELECTIVE ESTROGEN RECEPTOR DEGRADER ESR1, GPER1, ESR2 LMNA 4259/4885HTT 4080/4885SMN1; SMN2 2484/4885
US-11014915-B2 Selective estrogen receptor degrader ESR1, GPER1, ESR2 LMNA 4259/4885HTT 4080/4885SMN1; SMN2 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.